Sebastien Hazard

816 total citations
29 papers, 312 citations indexed

About

Sebastien Hazard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Sebastien Hazard has authored 29 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Reproductive Medicine. Recurrent topics in Sebastien Hazard's work include PARP inhibition in cancer therapy (14 papers), Ovarian cancer diagnosis and treatment (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Sebastien Hazard is often cited by papers focused on PARP inhibition in cancer therapy (14 papers), Ovarian cancer diagnosis and treatment (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Sebastien Hazard collaborates with scholars based in United States, Spain and Denmark. Sebastien Hazard's co-authors include Larry Leon, Suresh S. Ramalingam, Priscilla K. Brastianos, Mohammad Jahanzeb, E. Dawn Flick, Michael P. Kosty, Mansoor Raza Mirza, Julie R. Brahmer, Corey J. Langer and David R. Spigel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sebastien Hazard

29 papers receiving 305 citations

Peers

Sebastien Hazard
Eva María Guerra Alia Spain
B.J. Monk United States
Elena Giudice Italy
Carlos Linn United States
Gonghua Qi China
Gonzalo Giornelli Argentina
Imre Pete Hungary
Nicoletta Provinciali Italy
Koji Nishino Japan
Catrin Cox United Kingdom
Eva María Guerra Alia Spain
Sebastien Hazard
Citations per year, relative to Sebastien Hazard Sebastien Hazard (= 1×) peers Eva María Guerra Alia

Countries citing papers authored by Sebastien Hazard

Since Specialization
Citations

This map shows the geographic impact of Sebastien Hazard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sebastien Hazard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sebastien Hazard more than expected).

Fields of papers citing papers by Sebastien Hazard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sebastien Hazard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sebastien Hazard. The network helps show where Sebastien Hazard may publish in the future.

Co-authorship network of co-authors of Sebastien Hazard

This figure shows the co-authorship network connecting the top 25 collaborators of Sebastien Hazard. A scholar is included among the top collaborators of Sebastien Hazard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sebastien Hazard. Sebastien Hazard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baldini, Capucine, Irene Braña, Bernard Doger, et al.. (2023). BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).. Journal of Clinical Oncology. 41(6_suppl). 498–498. 13 indexed citations
2.
Spring, Laura M., Hyo S. Han, Minetta C. Liu, et al.. (2022). Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nature Cancer. 3(8). 927–931. 16 indexed citations
3.
Sharma, Geeta, et al.. (2021). Tissue distribution and brain penetration of niraparib in tumor bearing mouse models and its clinical relevance.. Journal of Clinical Oncology. 39(15_suppl). e15066–e15066. 4 indexed citations
4.
Ramalingam, Suresh S., Sukeshi Patel Arora, Jia Zhou, et al.. (2021). P83.02 Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study. Journal of Thoracic Oncology. 16(3). S653–S654. 1 indexed citations
5.
Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2019). Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology. 152(3). 560–567. 32 indexed citations
6.
Mirza, Mansoor Raza, Bin Feng, Ming Shan, et al.. (2019). Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.. Journal of Clinical Oncology. 37(15_suppl). 5568–5568. 2 indexed citations
7.
8.
Ratner, Elena, et al.. (2019). Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecologic Oncology. 153(3). 568–573. 31 indexed citations
9.
Ratner, Elena, et al.. (2018). Brain metastases in primary ovarian cancer: Real-world data. Annals of Oncology. 29. viii338–viii338. 3 indexed citations
10.
Lord, Rosemary, Mansoor Raza Mirza, Linn Woelber, et al.. (2018). Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology. 149. 11–11. 2 indexed citations
11.
Mirza, Mansoor Raza, Ignace Vergote, Sebastien Hazard, et al.. (2018). A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study. Annals of Oncology. 29. viii335–viii336. 10 indexed citations
12.
Mirza, Mansoor Raza, Lucy Gilbert, Michel Fabbro, et al.. (2017). The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial. Annals of Oncology. 28. v331–v332. 8 indexed citations
13.
Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2017). Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC). Annals of Oncology. 28. v332–v332. 7 indexed citations
14.
Lunacsek, Orsolya, Arliene Ravelo, Sebastien Hazard, et al.. (2016). First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices. Drugs - Real World Outcomes. 3(3). 333–343. 12 indexed citations
15.
16.
Woźniak, Agnieszka, Michael P. Kosty, Mohammad Jahanzeb, et al.. (2015). Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study. Clinical Oncology. 27(4). 187–196. 21 indexed citations
17.
Kosty, Michael P., Antoinette J. Wozniak, Mohammad Jahanzeb, et al.. (2015). Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study. Targeted Oncology. 10(4). 509–516. 5 indexed citations
18.
Langer, Corey J., Mark A. Socinski, Jyoti D. Patel, et al.. (2015). Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer. American Journal of Clinical Oncology. 39(5). 441–447. 35 indexed citations
19.
20.
Lynch, Thomas J., David R. Spigel, Julie R. Brahmer, et al.. (2014). Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study. Journal of Thoracic Oncology. 9(9). 1332–1339. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva María Guerra Alia Breakdown of academic impact, for papers by B.J. Monk Breakdown of academic impact, for papers by Elena Giudice Breakdown of academic impact, for papers by Carlos Linn Breakdown of academic impact, for papers by Gonghua Qi Breakdown of academic impact, for papers by Gonzalo Giornelli Breakdown of academic impact, for papers by Imre Pete Breakdown of academic impact, for papers by Nicoletta Provinciali Breakdown of academic impact, for papers by Koji Nishino Breakdown of academic impact, for papers by Catrin Cox
Rankless by CCL
2026